

U-CyTech B.V.

Yalelaan 48 3584 CM Utrecht The Netherlands +31 85 073 1460 info@ucytech.com www.ucytech.com Data sheet ICE Peptide Pool

Peptide pool of 32 HLA class I restricted T cell epitopes of human Influenza A

virus, Cytomegalovirus and Epstein-Barr virus.

Cat. No **CT387** 

Application

Specificity Intended for use as an antigen-specific positive control in for example the human

IFN-γ, IL-2 and G-CSF ELISPOT assay. The peptide pool consists of 32 peptides, each corresponding to 13 HLA class I restricted CD8+ T cells epitopes from human Influenza A virus (Flu), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV).

(Reference: Currier, J.R. et al. 2002. J. Immunol. Methods 260: 157-172)

Reconstitute the lyophilized content by injecting 250 µl of sterile distilled water into the vial. Mix the solution gently for approximately 15 seconds and allow it to

stand for 2 minutes at room temperature. Avoid vigorous shaking.

Working concentration: 40x in culture medium containing human PBMC Recommended peptide concentration:  $0.5~\mu g$  peptide/ml culture medium

Recommended cell concentration: 2x10<sup>5</sup> human PBMC/well Recommended culture volume in ELISPOT plate: 100 µl/well

Contents Lyophilized ICE peptide pool: 32 x 5 µg peptide/vial

Buffer prior to lyophilization: 0.25 ml PBS + 125 mM trehalose.

Preservative free

Contained VSDGGPNLY (Influenza A, HLA-A1), CTELKLSDY (Influenza A, HLA-A1), peptides

GILGFVFTL (Influenza A, HLA-A2), FMYSDFHFI (Influenza A, HLA-A2),

CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2),

NLVPMVATV (CMV, HLA-A2), KTGGPIYKR (Influenza A, HLA-A68), RVLSFIKGTK (Influenza A, HLA-A3), ILRGSVAHK (Influenza A, HLA-A3),

RVRAYTYSK (EBV, HLA-A3), RLRAEAQVK (EBV, HLA-A3),

SIIPSGPLK (Influenza A, HLA-A3/A11/A6), AVFDRKSDAK (EBV, HLA-A11),

IVTDFSVIK (EBV, HLA-A11), ATIGTAMYK (EBV, HLA-A11),

DYCNVLNKEF (EBV, HLA-A24), LPFDKTTVM (Influenza A, HLA-B7), RPPIFIRRL (EBV, HLA-B7), ELRSRYWAI (Influenza A, HLA-B8), RAKFKQLL (EBV, HLA-B8), FLRGRAYGL (EBV, HLA-B8),

QAKWRLQTL (EBV, HLA-B8), SDEEEAIVAYTL (CMV, HLA-B18),

SRYWAIRTR (Influenza A, HLA-B27), ASCMGLIY (Influenza A, HLA-B27),

RRIYDLIEL (EBV, HLA-B27), YPLHEQHGM (EBV, HLA-B35), IPSINVHHY (CMV, HLA-B35), EENLLDFVRF (EBV, HLA-B44) EFFWDANDIY (CMV, HLA-B44), TPRVTGGGAM (CMV, HLA-B7).

Sterility Membrane filtered (0.2 µm)

**Packaging** Brown glass bottle

The lyophilized peptide pool can be safely stored at 2 to 8 °C for a specified period Storage

of time (expiry date printed on vial).

After reconstitution, it is strongly recommended to divide the reconstituted

peptides into small aliquots for single use.

These aliquots should be stored at -32 to -18 °C. Under these conditions the

peptides are stable for at least two years.

General Clear powder (barely visible).

After reconstitution: a clear solution. Do not use if the solution is or has become

turbid.

The product is not classified as hazardous according to Regulation (EC) No Safety

Consult the safety data sheet (SDS) for further information regarding hazards and

safe handling. The SDS can be found on our website www.ucytech.com.

For research use only

**Version 250221**